I wonder whether someone at Bayer just found an old box of patent documents tucked in the corner of an office that hasn't been used in years.
The drugmaker is suing Abbott Labs
One has to wonder what took Bayer so long to file the lawsuit. The patent was issued in 1997, and Humira has been on the market for more than six years now. Maybe no one at Bayer noticed that the company owned the patent, but it seems just as likely that the drugmaker was waiting to see how large revenues from the drug could get before filing the infringement lawsuit. If the lawsuit is a shot in the dark, it might make sense to pay for the lawyers only if the long-shot potential royalty stream justifies the cost. And it just might pay off, if the company can get a cut of $4.4 billion, the drug's 2008 sales figure.
The anti-TNF market seems to be filled with patent infringement lawsuits -- not surprising, considering that the class of drugs brought in more than $11 billion cumulatively last year. Johnson & Johnson
Unless you're a patent attorney -- and perhaps even if you are -- it's rather difficult to figure out the chances that the companies will win these lawsuits. The best investors can do is hope that the companies they own hire good lawyers who can turn the tide in their favor.
Johnson & Johnson is an Income Investor recommendation. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter service with a 30-day free trial.
More from The Motley Fool
3 Top Diabetes Stocks to Buy Now
The diabetes market is growing. And these stocks are poised to grow with it.
Abbott Laboratories Q3 2017 Earnings Conference Call Transcript (ABT)
ABT earnings call for the period ending September 30, 2017
2 Great Stocks For Retirees
Find out what makes this pair of big pharma stocks a perfect fit for recent retirees looking to bolster their income.